PubMed:26264425 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/26264425","sourcedb":"PubMed","sourceid":"26264425","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/26264425","text":"Differential effects of strength training and testosterone treatment on soluble CD36 in aging men: Possible relation to changes in body composition.\nPURPOSE: We measured soluble CD36 (sCD36) and body composition to determine the effects of testosterone treatment (TT) and/or strength training (ST) on cardiovascular risk in men with low normal testosterone levels.\nMETHODS: Double-blinded, placebo-controlled study in 54 men aged 60-78 years with bioavailable testosterone \u003c 7.3 nmol/L and waist \u003e 94 cm randomized to TT (gel, 50-100 mg/day, n = 20), placebo (n = 18) or ST (n = 16) for 6 months. Moreover, the ST group was randomized to TT (ST + TT, n = 7) or placebo (ST + placebo, n = 9) after 3 months.\nOUTCOMES: sCD36, total and regional fat mass were established by Dual X-ray absorptiometry and magnetic resonance imaging. Data are presented as median (quartiles). Kruskal-Wallis and Mann-Whitney tests were performed on delta values at 0, 3 and 6 months.\nRESULTS: ST + placebo decreased sCD36 levels by 21% [from 0.80 (0.68-1.22) to 0.63 (0.51-0.73) rel. units] vs. TT and vs. placebo (p \u003c 0.05). ST + placebo did not change bioavailable testosterone and lean body mass. Fat mass measures significantly improved during ST + placebo, ST + TT, and TT vs. placebo. During ST + placebo, delta sCD36 was associated with delta total fat mass (r = 0.81) and delta central fat mass (r = 0.84).\nCONCLUSIONS: Compared to testosterone treatment, six months of strength training reduced sCD36 levels suggesting decreased cardiovascular risk, possibly due to a reduction in central fat mass.","tracks":[]}